Rigel Pharmaceuticals (RIGL)
(Real Time Quote from BATS)
$16.16 USD
+0.11 (0.69%)
Updated Oct 4, 2024 12:52 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Income Statements
Fiscal Year end for Rigel Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 117 | 120 | 149 | 109 | 59 |
Cost Of Goods | 7 | 2 | 1 | 1 | 1 |
Gross Profit | 110 | 118 | 148 | 108 | 58 |
Selling & Adminstrative & Depr. & Amort Expenses | 130 | 174 | 161 | 137 | 127 |
Income After Depreciation & Amortization | -20 | -56 | -13 | -29 | -69 |
Non-Operating Income | 2 | 1 | 0 | 1 | 3 |
Interest Expense | 7 | 4 | 5 | 1 | 0 |
Pretax Income | -25 | -59 | -17 | -30 | -67 |
Income Taxes | 0 | 0 | 1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -59 | -18 | -30 | -67 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -25 | -59 | -18 | -30 | -67 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -20 | -55 | -11 | -28 | -69 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -20 | -56 | -13 | -29 | -69 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 17.39 | 17.24 | 17.05 | 16.88 | 16.74 |
Diluted EPS Before Non-Recurring Items | -1.40 | -3.40 | -1.10 | -1.80 | -4.00 |
Diluted Net EPS (GAAP) | -1.40 | -3.40 | -1.10 | -1.80 | -4.00 |
Fiscal Year end for Rigel Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 36.84 | 29.53 | 35.79 | 28.13 | 26.89 |
Cost Of Goods | 2.81 | 2.03 | 3.79 | 1.27 | 1.08 |
Gross Profit | 34.03 | 27.51 | 32.00 | 26.87 | 25.81 |
SG&A, R&D, and Dept/Amort Expenses | 33.59 | 34.48 | 30.04 | 31.34 | 31.08 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.44 | -6.97 | 1.96 | -4.47 | -5.27 |
Non-Operating Income | 0.55 | 0.59 | 0.68 | 0.67 | 0.53 |
Interest Expense | 2.03 | 1.87 | 1.91 | 1.90 | 1.86 |
Pretax Income | -1.03 | -8.25 | 0.74 | -5.69 | -6.60 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.03 | -8.25 | 0.74 | -5.69 | -6.60 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.03 | -8.25 | 0.74 | -5.69 | -6.60 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 17.55 | 17.52 | 17.45 | 17.44 | 17.38 |
Diluted EPS Before Non-Recurring Items | -0.06 | -0.50 | 0.00 | -0.30 | -0.40 |
Diluted Net EPS (GAAP) | -0.06 | -0.50 | 0.10 | -0.30 | -0.40 |